(Reuters) -Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.
The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
Caris will start trading on the Nasdaq on Wednesday under the symbol ‘CAI’.
(Reporting by Arasu Kannagi Basil and Pritam Biswas in Bengaluru; Editing by Shreya Biswas)
Comments